Sodium triacetoxyborohydride → HCID 178504212, compound
Reaction equation
Cl.Cl.C[Si](C)(C)CCOCN1C2N=CN=C(C3C=NN(C4(CC#N)CNC4)C=3)C=2C=C1.OCC1C=C(C(F)(F)F)N=C(OC2CCC(=O)CC2)C=1.C(O[BH-](OC(=O)C)OC(=O)C)(=O)C.[Na+].[OH:66][CH2:67][C:68]1[CH:73]=[C:72]([C:74]([F:77])([F:76])[F:75])[N:71]=[C:70]([O:78][C@H:79]2[CH2:84][CH2:83][C@H:82]([N:85]3[CH2:88][C:87]([CH2:111][C:112]#[N:113])([N:89]4[CH:93]=[C:92]([C:94]5[C:95]6[CH:102]=[CH:101][N:100]([CH2:103][O:104][CH2:105][CH2:106][Si:107]([CH3:110])([CH3:109])[CH3:108])[C:96]=6[N:97]=[CH:98][N:99]=5)[CH:91]=[N:90]4)[CH2:86]3)[CH2:81][CH2:80]2)[CH:69]=1>ClCCCl>[OH:66][CH2:67][C:68]1[CH:73]=[C:72]([C:74]([F:75])([F:77])[F:76])[N:71]=[C:70]([O:78][C@@H:79]2[CH2:80][CH2:81][C@H:82]([N:85]3[CH2:86][C:87]([CH2:111][C:112]#[N:113])([N:89]4[CH:93]=[C:92]([C:94]5[C:95]6[CH:102]=[CH:101][N:100]([CH2:103][O:104][CH2:105][CH2:106][Si:107]([CH3:108])([CH3:109])[CH3:110])[C:96]=6[N:97]=[CH:98][N:99]=5)[CH:91]=[N:90]4)[CH2:88]3)[CH2:83][CH2:84]2)[CH:69]=1Participants
Reactant 4
Product 1
Reagents, catalysts & solvents 1
Procedure
{3-[4-(7-{[2-(Trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile dihydrochloride (400.0 mg, 0.829 mmol) and 4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexanone (300.0 mg, 1.037 mmol) were mixed in dry 1,2-dichloroethane (11.33 mL) and were stirred for 5 minutes. Sodium triacetoxyborohydride (708 mg, 3.34 mmol) was added to this mixture. The reaction mixture was stirred at 25 C for 16 hours, at which time LCMS analysis showed mainly the two diastereomeric products. The reaction was quenched with water, neutralized with NaHCO3 and extracted with ethyl acetate and the solvent was evaporated. The residue was purified by LCMS (pH 10) and the fractions containing the second peak were combined and evaporated to give 1-(cis-4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7-{[2-(trimethyl silyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile. MS (ES): 683 (M+1). The first peak contained {1-(trans-4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile. MS (ES): 683 (M+1).
Workup
- stirringThe reaction mixture was stirred at 25 C for 16 hours, at which time LCMS analysis
- customThe reaction was quenched with water
- extractionextracted with ethyl acetate
- customthe solvent was evaporated
- customThe residue was purified by LCMS (pH 10)
- additionthe fractions containing the second peak
- customevaporated
- customto give 1-(cis-4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7-{[2-(trimethyl silyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile
Sources & evidence
- ORD record
- ord-734977e33c7b4ffdb417a47d7be4ee54
- Source dataset
- uspto-grants-2016_06
- Patent number
- US09359358B2
Reaction notes
Loading…